ChinaOverall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Nanoscience & Nanotechnology
Rank in SubField 1: 2,920 out of 157,499 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 346,554 | 346,293 |
| Total Cites | 447 | 511 |
| H-index | 10 | 11 |
| Hm-index | 4 | 4 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 11 | 11 |
| Total Cites to Single+First Authored Papers | 11 | 11 |
| Number of Single+First+Last Authored Papers | 73 | 73 |
| Total Cites to Single+First+Last Authored Papers | 370 | 425 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 375 | 392 |
| Ratio of Total Citations to Distinct Citing Papers | 1.19 | 1.30 |
| Self-Citation Percentage |
12.52%
|
|
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Nanoscience & Nanotechnology
Rank in SubField 1: 2,576 out of 148,458 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 312,937 | 330,197 |
| Total Cites | 454 | 508 |
| H-index | 11 | 12 |
| Hm-index | 3 | 3 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 11 | 11 |
| Total Cites to Single+First Authored Papers | 13 | 13 |
| Number of Single+First+Last Authored Papers | 66 | 66 |
| Total Cites to Single+First+Last Authored Papers | 379 | 418 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 342 | 359 |
| Ratio of Total Citations to Distinct Citing Papers | 1.33 | 1.42 |
| Self-Citation Percentage |
10.63%
|
|
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Nanoscience & Nanotechnology
Rank in SubField 1: 1,617 out of 140,593 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 208,895 | 202,612 |
| Total Cites | 518 | 595 |
| H-index | 11 | 13 |
| Hm-index | 4 | 5 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 11 | 11 |
| Total Cites to Single+First Authored Papers | 30 | 30 |
| Number of Single+First+Last Authored Papers | 60 | 60 |
| Total Cites to Single+First+Last Authored Papers | 436 | 491 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 391 | 411 |
| Ratio of Total Citations to Distinct Citing Papers | 1.32 | 1.45 |
| Self-Citation Percentage |
12.94%
|
|
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Chemistry
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Nanoscience & Nanotechnology
Rank in SubField 1: 2,312 out of 134,745 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 282,397 | 325,575 |
| Total Cites | 380 | 412 |
| H-index | 10 | 10 |
| Hm-index | 3 | 3 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 11 | 11 |
| Total Cites to Single+First Authored Papers | 24 | 24 |
| Number of Single+First+Last Authored Papers | 56 | 56 |
| Total Cites to Single+First+Last Authored Papers | 300 | 318 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 307 | 321 |
| Ratio of Total Citations to Distinct Citing Papers | 1.24 | 1.28 |
| Self-Citation Percentage |
7.77%
|
|
Related Profiles
Top 2% Scientists by Country
236,132 scientists from 167 countries on the 2025 single-year list.
China31,697 scientists, 2nd in the world
Featured Profiles
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.